Journal of Medical Physics and Applied Sciences

PET radiopharmaceuticals production facilities, planning and operation challenges

International Conference on Nuclear Medicine & Radiation Therapy
October 01- 02 , 2018 Stockholm , Sweden

Tamer B Bayomy

International Medical Centre, Egypt

ScientificTracks Abstracts: J. med phys & appl sci 2018

DOI: 10.21767/2574-285X-C1-002

Abstract

Cyclotron facilities are relatively long lived solutions. Having a production facility complying with the international standards of good manufacturing practice (GMP) can be only achieved by a well-planed road map. The scope of services provided by the facility and how much it is incorporated in the national research and production activities is defining how it should be planned and operated. The production facility can’t be limited only to the cyclotron products but should be designed to accommodate all PET and some SPECT radionuclide production technologies to act as a central nuclear pharmacy for the local area.

Biography

Tamer B Bayomy has completed his PhD from Cairo University. He was serving as an Expert /Lecturer for the IAEA since 2010. He was granted as a Member of the American Board in Radiopharmacy in June 2014. He is the Head of the Cyclotron Department, International Medical Centre, Cairo, Egypt since 2016. He worked as the Head of Cyclotron in King Hamad University Hospital, Bahrain from 2012 to 2016. He also has worked as Senior Radiopharmacist and an Acting Cyclotron Head (2005- 2012) in King Fahd Specialist Hospital, Saudi Arabia.

E-mail: tamirbayomy@yahoo.com